FDA Approves New Alzheimer's Drug

The Food and Drug Administration approved a new drug shown to slow the progression of early stage Alzheimer's.

The drug, known as Lecanemab, has been approved after an 18-month long study.

The Alzheimer's Association said the treatment a milestone achievement, and the group is now calling on the Centers for Medicare and Medicaid Services to cover the drug under insurance after denying it coverage months ago.